Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

dendreon uk ltd - autológne periférne krvné mononukleárnych buniek vrátane minimálne 50 miliónov autológne cd54 + bunky aktivované s prostaty kyseliny fosfatázy granulocytov makrofágov faktor stimulujúci kolónie - prostatické nádory - iné imunostimulanty - provenge je indikovaný na liečbu asymptomatické alebo minimálne symptomatická metastatického (neviscerálnemu) vykastrovať-rezistentné karcinómu prostaty u dospelých mužov, u ktorých chemoterapia je doposiaľ nebola klinicky indikovaná.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastické činidlá - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - viacnásobný myelóm - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - viacnásobný myelóm - antineoplastické činidlá - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - formoterol - 14 - bronchodilatantia, antiasthmatica

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - formoterol a budezonid - 14 - bronchodilatantia, antiasthmatica

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - formoterol a budezonid - 14 - bronchodilatantia, antiasthmatica

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

nova laboratories ireland limited - 6-merkaptopurín monohydrát - leukémia, lymfóza - antineoplastické činidlá - xaluprin je indikovaný na liečbu akútnej lymfoblastickej leukémie (all) u dospelých, dospievajúcich a detí.